Lawyer Paul Dopson will recap the Wyeth decision and recent decisions of the Court of State and discuss how Wyeth has impacted — and probably will continue to impact — generic drug manufacturers. This webinar also will examine:
Trends in product liability litigation related to pharmacovigilance the need for impact of "transparency" in all in a company Wyeth in the development of labels and warnings implications for trends and recommendations risk management
Paul k. Dopson, J.D., is a partner at the San Francisco of Wilson Elser Moskowitz Edelman & Dicker LLP. She is a former nurse and head of its Oncology practice focuses on the defense of pharmaceutical and medical device manufacturers, as well as personal injury and employment discrimination matters.
During his career, Paul has served as a national Steering Committee and managed litigation for pharmaceutical and medical device manufacturers in multi/multi state plaintiffs litigation. She is currently coordinating national lawyer defending a trademark litigation of quinine. She represented the brand and generic pharmaceutical companies and defended a wide variety of medical device manufacturers.
Paul was appointed the defense lawyer of Medmarc insurance company of the year in 2005. She served on the editorial board of MX magazine, a publication that served the medical device industry.
This post was made using the Auto Blogging Software from WebMagnates.org This line will not appear when posts are made after activating the software to full version.
